nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—Menstruation irregular—Spironolactone—dilated cardiomyopathy	0.0146	0.0253	CcSEcCtD
Paliperidone—Polydipsia—Furosemide—dilated cardiomyopathy	0.0142	0.0246	CcSEcCtD
Paliperidone—Tetany—Furosemide—dilated cardiomyopathy	0.0135	0.0234	CcSEcCtD
Paliperidone—Drug eruption—Spironolactone—dilated cardiomyopathy	0.0132	0.0228	CcSEcCtD
Paliperidone—Breast enlargement—Spironolactone—dilated cardiomyopathy	0.0125	0.0216	CcSEcCtD
Paliperidone—Shoulder pain—Lisinopril—dilated cardiomyopathy	0.0123	0.0212	CcSEcCtD
Paliperidone—Blood cholesterol increased—Furosemide—dilated cardiomyopathy	0.011	0.0189	CcSEcCtD
Paliperidone—Breast pain—Spironolactone—dilated cardiomyopathy	0.0093	0.016	CcSEcCtD
Paliperidone—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00923	0.0159	CcSEcCtD
Paliperidone—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.00726	0.0125	CcSEcCtD
Paliperidone—Drug eruption—Furosemide—dilated cardiomyopathy	0.00717	0.0124	CcSEcCtD
Paliperidone—Cerebral ischaemia—Lisinopril—dilated cardiomyopathy	0.00685	0.0118	CcSEcCtD
Paliperidone—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00673	0.0116	CcSEcCtD
Paliperidone—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.00656	0.0113	CcSEcCtD
Paliperidone—Lethargy—Spironolactone—dilated cardiomyopathy	0.00601	0.0104	CcSEcCtD
Paliperidone—Inappropriate antidiuretic hormone secretion—Lisinopril—dilated cardiomyopathy	0.0057	0.00983	CcSEcCtD
Paliperidone—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.00557	0.00961	CcSEcCtD
Paliperidone—Glycosuria—Furosemide—dilated cardiomyopathy	0.00545	0.0094	CcSEcCtD
Paliperidone—Injection site pain—Furosemide—dilated cardiomyopathy	0.0054	0.00933	CcSEcCtD
Paliperidone—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.00509	0.00879	CcSEcCtD
Paliperidone—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00469	0.00809	CcSEcCtD
Paliperidone—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.00432	0.00746	CcSEcCtD
Paliperidone—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00423	0.00731	CcSEcCtD
Paliperidone—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00399	0.00689	CcSEcCtD
Paliperidone—Bladder pain—Furosemide—dilated cardiomyopathy	0.00399	0.00688	CcSEcCtD
Paliperidone—Breast pain—Lisinopril—dilated cardiomyopathy	0.00379	0.00655	CcSEcCtD
Paliperidone—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.00374	0.00646	CcSEcCtD
Paliperidone—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00368	0.00635	CcSEcCtD
Paliperidone—Viral infection—Lisinopril—dilated cardiomyopathy	0.00367	0.00633	CcSEcCtD
Paliperidone—Swelling—Furosemide—dilated cardiomyopathy	0.00363	0.00627	CcSEcCtD
Paliperidone—Alopecia—Spironolactone—dilated cardiomyopathy	0.0036	0.00621	CcSEcCtD
Paliperidone—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00341	0.00588	CcSEcCtD
Paliperidone—Thirst—Furosemide—dilated cardiomyopathy	0.00337	0.00581	CcSEcCtD
Paliperidone—Neck pain—Lisinopril—dilated cardiomyopathy	0.00335	0.00578	CcSEcCtD
Paliperidone—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00335	0.00578	CcSEcCtD
Paliperidone—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00331	0.00571	CcSEcCtD
Paliperidone—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00331	0.00571	CcSEcCtD
Paliperidone—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00329	0.00568	CcSEcCtD
Paliperidone—Lethargy—Furosemide—dilated cardiomyopathy	0.00327	0.00564	CcSEcCtD
Paliperidone—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00323	0.00558	CcSEcCtD
Paliperidone—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00322	0.00555	CcSEcCtD
Paliperidone—Wheezing—Lisinopril—dilated cardiomyopathy	0.00322	0.00555	CcSEcCtD
Paliperidone—Malaise—Spironolactone—dilated cardiomyopathy	0.0032	0.00552	CcSEcCtD
Paliperidone—Cystitis—Lisinopril—dilated cardiomyopathy	0.0032	0.00552	CcSEcCtD
Paliperidone—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00317	0.00548	CcSEcCtD
Paliperidone—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00314	0.00542	CcSEcCtD
Paliperidone—Photophobia—Lisinopril—dilated cardiomyopathy	0.00311	0.00536	CcSEcCtD
Paliperidone—Urinary retention—Furosemide—dilated cardiomyopathy	0.00305	0.00526	CcSEcCtD
Paliperidone—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00299	0.00517	CcSEcCtD
Paliperidone—Discomfort—Spironolactone—dilated cardiomyopathy	0.00298	0.00515	CcSEcCtD
Paliperidone—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00293	0.00505	CcSEcCtD
Paliperidone—Confusional state—Spironolactone—dilated cardiomyopathy	0.00292	0.00503	CcSEcCtD
Paliperidone—Hypertonia—Lisinopril—dilated cardiomyopathy	0.0029	0.00501	CcSEcCtD
Paliperidone—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00289	0.00499	CcSEcCtD
Paliperidone—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00283	0.00489	CcSEcCtD
Paliperidone—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00282	0.00488	CcSEcCtD
Paliperidone—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00278	0.00479	CcSEcCtD
Paliperidone—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00276	0.00477	CcSEcCtD
Paliperidone—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00271	0.00468	CcSEcCtD
Paliperidone—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00271	0.00468	CcSEcCtD
Paliperidone—Eczema—Lisinopril—dilated cardiomyopathy	0.00267	0.00461	CcSEcCtD
Paliperidone—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00264	0.00455	CcSEcCtD
Paliperidone—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00259	0.00447	CcSEcCtD
Paliperidone—Somnolence—Spironolactone—dilated cardiomyopathy	0.00257	0.00444	CcSEcCtD
Paliperidone—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00256	0.00441	CcSEcCtD
Paliperidone—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00254	0.00438	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0025	0.00431	CcSEcCtD
Paliperidone—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.0025	0.00431	CcSEcCtD
Paliperidone—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00246	0.00425	CcSEcCtD
Paliperidone—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00245	0.00423	CcSEcCtD
Paliperidone—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.0024	0.00415	CcSEcCtD
Paliperidone—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.0024	0.00415	CcSEcCtD
Paliperidone—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00238	0.00411	CcSEcCtD
Paliperidone—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00238	0.00411	CcSEcCtD
Paliperidone—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00233	0.00403	CcSEcCtD
Paliperidone—Face oedema—Lisinopril—dilated cardiomyopathy	0.00232	0.004	CcSEcCtD
Paliperidone—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.0023	0.00398	CcSEcCtD
Paliperidone—Urticaria—Spironolactone—dilated cardiomyopathy	0.0023	0.00397	CcSEcCtD
Paliperidone—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00229	0.00395	CcSEcCtD
Paliperidone—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00229	0.00394	CcSEcCtD
Paliperidone—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00219	0.00379	CcSEcCtD
Paliperidone—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00219	0.00378	CcSEcCtD
Paliperidone—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00217	0.00375	CcSEcCtD
Paliperidone—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00217	0.00375	CcSEcCtD
Paliperidone—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00215	0.00371	CcSEcCtD
Paliperidone—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00213	0.00368	CcSEcCtD
Paliperidone—Influenza—Lisinopril—dilated cardiomyopathy	0.00208	0.00358	CcSEcCtD
Paliperidone—Eye disorder—Furosemide—dilated cardiomyopathy	0.00207	0.00357	CcSEcCtD
Paliperidone—Tinnitus—Furosemide—dilated cardiomyopathy	0.00207	0.00357	CcSEcCtD
Paliperidone—Pruritus—Spironolactone—dilated cardiomyopathy	0.00205	0.00353	CcSEcCtD
Paliperidone—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00204	0.00351	CcSEcCtD
Paliperidone—Angiopathy—Furosemide—dilated cardiomyopathy	0.00201	0.00347	CcSEcCtD
Paliperidone—Immune system disorder—Furosemide—dilated cardiomyopathy	0.002	0.00345	CcSEcCtD
Paliperidone—Bronchitis—Lisinopril—dilated cardiomyopathy	0.002	0.00345	CcSEcCtD
Paliperidone—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00198	0.00342	CcSEcCtD
Paliperidone—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00194	0.00335	CcSEcCtD
Paliperidone—Dysuria—Lisinopril—dilated cardiomyopathy	0.00194	0.00335	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00193	0.00333	CcSEcCtD
Paliperidone—Erythema—Furosemide—dilated cardiomyopathy	0.00193	0.00333	CcSEcCtD
Paliperidone—Malnutrition—Furosemide—dilated cardiomyopathy	0.00193	0.00333	CcSEcCtD
Paliperidone—Dizziness—Spironolactone—dilated cardiomyopathy	0.00191	0.0033	CcSEcCtD
Paliperidone—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00191	0.0033	CcSEcCtD
Paliperidone—Flatulence—Furosemide—dilated cardiomyopathy	0.0019	0.00328	CcSEcCtD
Paliperidone—Weight increased—Lisinopril—dilated cardiomyopathy	0.00189	0.00326	CcSEcCtD
Paliperidone—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00189	0.00326	CcSEcCtD
Paliperidone—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00188	0.00324	CcSEcCtD
Paliperidone—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00187	0.00323	CcSEcCtD
Paliperidone—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00186	0.00321	CcSEcCtD
Paliperidone—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00185	0.0032	CcSEcCtD
Paliperidone—Depression—Lisinopril—dilated cardiomyopathy	0.00185	0.00319	CcSEcCtD
Paliperidone—Vomiting—Spironolactone—dilated cardiomyopathy	0.00184	0.00317	CcSEcCtD
Paliperidone—Rash—Spironolactone—dilated cardiomyopathy	0.00182	0.00315	CcSEcCtD
Paliperidone—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00182	0.00315	CcSEcCtD
Paliperidone—Vision blurred—Furosemide—dilated cardiomyopathy	0.00182	0.00314	CcSEcCtD
Paliperidone—Headache—Spironolactone—dilated cardiomyopathy	0.00181	0.00313	CcSEcCtD
Paliperidone—Jaundice—Lisinopril—dilated cardiomyopathy	0.00181	0.00312	CcSEcCtD
Paliperidone—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.0018	0.00311	CcSEcCtD
Paliperidone—Anaemia—Furosemide—dilated cardiomyopathy	0.00178	0.00308	CcSEcCtD
Paliperidone—Agitation—Furosemide—dilated cardiomyopathy	0.00177	0.00306	CcSEcCtD
Paliperidone—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00175	0.00302	CcSEcCtD
Paliperidone—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00175	0.00301	CcSEcCtD
Paliperidone—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00174	0.003	CcSEcCtD
Paliperidone—Vertigo—Furosemide—dilated cardiomyopathy	0.00173	0.00299	CcSEcCtD
Paliperidone—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00173	0.00298	CcSEcCtD
Paliperidone—Leukopenia—Furosemide—dilated cardiomyopathy	0.00173	0.00298	CcSEcCtD
Paliperidone—Nausea—Spironolactone—dilated cardiomyopathy	0.00172	0.00297	CcSEcCtD
Paliperidone—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00169	0.00292	CcSEcCtD
Paliperidone—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00167	0.00288	CcSEcCtD
Paliperidone—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00164	0.00283	CcSEcCtD
Paliperidone—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00164	0.00283	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00163	0.00281	CcSEcCtD
Paliperidone—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00163	0.00281	CcSEcCtD
Paliperidone—Dry mouth—Furosemide—dilated cardiomyopathy	0.00161	0.00277	CcSEcCtD
Paliperidone—Confusional state—Furosemide—dilated cardiomyopathy	0.00159	0.00274	CcSEcCtD
Paliperidone—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00157	0.00272	CcSEcCtD
Paliperidone—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00155	0.00268	CcSEcCtD
Paliperidone—Shock—Furosemide—dilated cardiomyopathy	0.00155	0.00267	CcSEcCtD
Paliperidone—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00154	0.00266	CcSEcCtD
Paliperidone—Flushing—Lisinopril—dilated cardiomyopathy	0.00154	0.00266	CcSEcCtD
Paliperidone—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00154	0.00266	CcSEcCtD
Paliperidone—Skin disorder—Furosemide—dilated cardiomyopathy	0.00153	0.00264	CcSEcCtD
Paliperidone—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00151	0.0026	CcSEcCtD
Paliperidone—Anorexia—Furosemide—dilated cardiomyopathy	0.0015	0.00259	CcSEcCtD
Paliperidone—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.0015	0.00259	CcSEcCtD
Paliperidone—Chills—Lisinopril—dilated cardiomyopathy	0.00149	0.00257	CcSEcCtD
Paliperidone—Hypotension—Furosemide—dilated cardiomyopathy	0.00147	0.00254	CcSEcCtD
Paliperidone—Alopecia—Lisinopril—dilated cardiomyopathy	0.00147	0.00254	CcSEcCtD
Paliperidone—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00146	0.00251	CcSEcCtD
Paliperidone—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00145	0.0025	CcSEcCtD
Paliperidone—Erythema—Lisinopril—dilated cardiomyopathy	0.00145	0.0025	CcSEcCtD
Paliperidone—Flatulence—Lisinopril—dilated cardiomyopathy	0.00143	0.00246	CcSEcCtD
Paliperidone—Tension—Lisinopril—dilated cardiomyopathy	0.00142	0.00245	CcSEcCtD
Paliperidone—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00142	0.00245	CcSEcCtD
Paliperidone—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00141	0.00244	CcSEcCtD
Paliperidone—Nervousness—Lisinopril—dilated cardiomyopathy	0.00141	0.00243	CcSEcCtD
Paliperidone—Back pain—Lisinopril—dilated cardiomyopathy	0.0014	0.00242	CcSEcCtD
Paliperidone—Somnolence—Furosemide—dilated cardiomyopathy	0.0014	0.00242	CcSEcCtD
Paliperidone—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00139	0.0024	CcSEcCtD
Paliperidone—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00137	0.00236	CcSEcCtD
Paliperidone—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00136	0.00235	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00136	0.00235	CcSEcCtD
Paliperidone—Fatigue—Furosemide—dilated cardiomyopathy	0.00136	0.00234	CcSEcCtD
Paliperidone—Tremor—Lisinopril—dilated cardiomyopathy	0.00136	0.00234	CcSEcCtD
Paliperidone—Pain—Furosemide—dilated cardiomyopathy	0.00135	0.00232	CcSEcCtD
Paliperidone—Constipation—Furosemide—dilated cardiomyopathy	0.00135	0.00232	CcSEcCtD
Paliperidone—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00134	0.00232	CcSEcCtD
Paliperidone—Anaemia—Lisinopril—dilated cardiomyopathy	0.00134	0.00231	CcSEcCtD
Paliperidone—Angioedema—Lisinopril—dilated cardiomyopathy	0.00132	0.00228	CcSEcCtD
Paliperidone—Malaise—Lisinopril—dilated cardiomyopathy	0.00131	0.00225	CcSEcCtD
Paliperidone—Vertigo—Lisinopril—dilated cardiomyopathy	0.0013	0.00224	CcSEcCtD
Paliperidone—Syncope—Lisinopril—dilated cardiomyopathy	0.0013	0.00224	CcSEcCtD
Paliperidone—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.0013	0.00224	CcSEcCtD
Paliperidone—Leukopenia—Lisinopril—dilated cardiomyopathy	0.0013	0.00224	CcSEcCtD
Paliperidone—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00129	0.00222	CcSEcCtD
Paliperidone—Palpitations—Lisinopril—dilated cardiomyopathy	0.00128	0.00221	CcSEcCtD
Paliperidone—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00127	0.0022	CcSEcCtD
Paliperidone—Cough—Lisinopril—dilated cardiomyopathy	0.00126	0.00218	CcSEcCtD
Paliperidone—Urticaria—Furosemide—dilated cardiomyopathy	0.00125	0.00216	CcSEcCtD
Paliperidone—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00124	0.00215	CcSEcCtD
Paliperidone—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00124	0.00215	CcSEcCtD
Paliperidone—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00123	0.00213	CcSEcCtD
Paliperidone—Chest pain—Lisinopril—dilated cardiomyopathy	0.00123	0.00213	CcSEcCtD
Paliperidone—Myalgia—Lisinopril—dilated cardiomyopathy	0.00123	0.00213	CcSEcCtD
Paliperidone—Anxiety—Lisinopril—dilated cardiomyopathy	0.00123	0.00212	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00122	0.00211	CcSEcCtD
Paliperidone—Discomfort—Lisinopril—dilated cardiomyopathy	0.00122	0.0021	CcSEcCtD
Paliperidone—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00121	0.00208	CcSEcCtD
Paliperidone—Confusional state—Lisinopril—dilated cardiomyopathy	0.00119	0.00206	CcSEcCtD
Paliperidone—Oedema—Lisinopril—dilated cardiomyopathy	0.00118	0.00204	CcSEcCtD
Paliperidone—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00118	0.00204	CcSEcCtD
Paliperidone—Infection—Lisinopril—dilated cardiomyopathy	0.00117	0.00203	CcSEcCtD
Paliperidone—Shock—Lisinopril—dilated cardiomyopathy	0.00116	0.00201	CcSEcCtD
Paliperidone—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00116	0.002	CcSEcCtD
Paliperidone—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00116	0.002	CcSEcCtD
Paliperidone—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00115	0.00199	CcSEcCtD
Paliperidone—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00115	0.00198	CcSEcCtD
Paliperidone—Asthenia—Furosemide—dilated cardiomyopathy	0.00113	0.00195	CcSEcCtD
Paliperidone—Anorexia—Lisinopril—dilated cardiomyopathy	0.00113	0.00194	CcSEcCtD
Paliperidone—Pruritus—Furosemide—dilated cardiomyopathy	0.00111	0.00192	CcSEcCtD
Paliperidone—Hypotension—Lisinopril—dilated cardiomyopathy	0.0011	0.0019	CcSEcCtD
Paliperidone—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00108	0.00186	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00108	0.00186	CcSEcCtD
Paliperidone—Insomnia—Lisinopril—dilated cardiomyopathy	0.00107	0.00184	CcSEcCtD
Paliperidone—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00106	0.00183	CcSEcCtD
Paliperidone—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00105	0.00182	CcSEcCtD
Paliperidone—Somnolence—Lisinopril—dilated cardiomyopathy	0.00105	0.00181	CcSEcCtD
Paliperidone—Dizziness—Furosemide—dilated cardiomyopathy	0.00104	0.0018	CcSEcCtD
Paliperidone—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00104	0.00179	CcSEcCtD
Paliperidone—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00103	0.00177	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00102	0.00176	CcSEcCtD
Paliperidone—Fatigue—Lisinopril—dilated cardiomyopathy	0.00102	0.00176	CcSEcCtD
Paliperidone—Constipation—Lisinopril—dilated cardiomyopathy	0.00101	0.00174	CcSEcCtD
Paliperidone—Pain—Lisinopril—dilated cardiomyopathy	0.00101	0.00174	CcSEcCtD
Paliperidone—Vomiting—Furosemide—dilated cardiomyopathy	0.001	0.00173	CcSEcCtD
Paliperidone—Rash—Furosemide—dilated cardiomyopathy	0.000993	0.00171	CcSEcCtD
Paliperidone—Dermatitis—Furosemide—dilated cardiomyopathy	0.000992	0.00171	CcSEcCtD
Paliperidone—Headache—Furosemide—dilated cardiomyopathy	0.000986	0.0017	CcSEcCtD
Paliperidone—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000973	0.00168	CcSEcCtD
Paliperidone—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000966	0.00167	CcSEcCtD
Paliperidone—Urticaria—Lisinopril—dilated cardiomyopathy	0.000938	0.00162	CcSEcCtD
Paliperidone—Nausea—Furosemide—dilated cardiomyopathy	0.000935	0.00161	CcSEcCtD
Paliperidone—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000934	0.00161	CcSEcCtD
Paliperidone—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000934	0.00161	CcSEcCtD
Paliperidone—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00087	0.0015	CcSEcCtD
Paliperidone—Asthenia—Lisinopril—dilated cardiomyopathy	0.000847	0.00146	CcSEcCtD
Paliperidone—Pruritus—Lisinopril—dilated cardiomyopathy	0.000836	0.00144	CcSEcCtD
Paliperidone—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000808	0.00139	CcSEcCtD
Paliperidone—Dizziness—Lisinopril—dilated cardiomyopathy	0.000781	0.00135	CcSEcCtD
Paliperidone—Vomiting—Lisinopril—dilated cardiomyopathy	0.000751	0.0013	CcSEcCtD
Paliperidone—Rash—Lisinopril—dilated cardiomyopathy	0.000745	0.00129	CcSEcCtD
Paliperidone—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000744	0.00128	CcSEcCtD
Paliperidone—Headache—Lisinopril—dilated cardiomyopathy	0.00074	0.00128	CcSEcCtD
Paliperidone—Nausea—Lisinopril—dilated cardiomyopathy	0.000702	0.00121	CcSEcCtD
Paliperidone—ADRA2C—Hemostasis—RAF1—dilated cardiomyopathy	0.000101	0.000241	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000101	0.00024	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000101	0.00024	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000101	0.00024	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000101	0.00024	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000101	0.000239	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000101	0.000239	CbGpPWpGaD
Paliperidone—HTR1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.97e-05	0.000237	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—AGT—dilated cardiomyopathy	9.93e-05	0.000236	CbGpPWpGaD
Paliperidone—HTR2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.92e-05	0.000236	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.89e-05	0.000235	CbGpPWpGaD
Paliperidone—ADRA2B—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.87e-05	0.000235	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	9.86e-05	0.000235	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.78e-05	0.000233	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.78e-05	0.000233	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.76e-05	0.000232	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.74e-05	0.000232	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	9.66e-05	0.00023	CbGpPWpGaD
Paliperidone—ADRA2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.65e-05	0.000229	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.53e-05	0.000227	CbGpPWpGaD
Paliperidone—HTR1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.53e-05	0.000227	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	9.5e-05	0.000226	CbGpPWpGaD
Paliperidone—ADRA1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.49e-05	0.000226	CbGpPWpGaD
Paliperidone—HTR2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.48e-05	0.000225	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.44e-05	0.000225	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.44e-05	0.000225	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.39e-05	0.000223	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.39e-05	0.000223	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.38e-05	0.000223	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—RAC1—dilated cardiomyopathy	9.38e-05	0.000223	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.34e-05	0.000222	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.24e-05	0.00022	CbGpPWpGaD
Paliperidone—ADRA2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.22e-05	0.000219	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.19e-05	0.000218	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.17e-05	0.000218	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	9.17e-05	0.000218	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.14e-05	0.000217	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.14e-05	0.000217	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.09e-05	0.000216	CbGpPWpGaD
Paliperidone—ADRA1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.07e-05	0.000216	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	9.05e-05	0.000215	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.04e-05	0.000215	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	9.01e-05	0.000214	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	9e-05	0.000214	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.99e-05	0.000214	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.99e-05	0.000214	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—AGT—dilated cardiomyopathy	8.96e-05	0.000213	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.9e-05	0.000212	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.81e-05	0.000209	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.78e-05	0.000209	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.76e-05	0.000208	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.75e-05	0.000208	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.73e-05	0.000208	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—AGT—dilated cardiomyopathy	8.65e-05	0.000206	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.62e-05	0.000205	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.61e-05	0.000205	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—AGT—dilated cardiomyopathy	8.61e-05	0.000205	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.59e-05	0.000204	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	8.59e-05	0.000204	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.5e-05	0.000202	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.5e-05	0.000202	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.46e-05	0.000201	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.44e-05	0.000201	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.43e-05	0.000201	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—AGT—dilated cardiomyopathy	8.37e-05	0.000199	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.36e-05	0.000199	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.36e-05	0.000199	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.36e-05	0.000199	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.33e-05	0.000198	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.29e-05	0.000197	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.29e-05	0.000197	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AGT—dilated cardiomyopathy	8.24e-05	0.000196	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.23e-05	0.000196	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.23e-05	0.000196	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—RAF1—dilated cardiomyopathy	8.22e-05	0.000196	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.21e-05	0.000195	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.16e-05	0.000194	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.16e-05	0.000194	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.14e-05	0.000194	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.14e-05	0.000194	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.1e-05	0.000193	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.06e-05	0.000192	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.05e-05	0.000191	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.01e-05	0.000191	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.99e-05	0.00019	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.99e-05	0.00019	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.95e-05	0.000189	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.94e-05	0.000189	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.9e-05	0.000188	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	7.88e-05	0.000187	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.84e-05	0.000186	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.82e-05	0.000186	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.8e-05	0.000186	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.77e-05	0.000185	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—RAF1—dilated cardiomyopathy	7.75e-05	0.000184	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.71e-05	0.000183	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.66e-05	0.000182	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.65e-05	0.000182	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AGT—dilated cardiomyopathy	7.59e-05	0.000181	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.58e-05	0.00018	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.57e-05	0.00018	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.52e-05	0.000179	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.49e-05	0.000178	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AGT—dilated cardiomyopathy	7.47e-05	0.000178	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.47e-05	0.000178	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AGT—dilated cardiomyopathy	7.46e-05	0.000177	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.43e-05	0.000177	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.42e-05	0.000176	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.42e-05	0.000176	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.35e-05	0.000175	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.33e-05	0.000174	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	7.32e-05	0.000174	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.26e-05	0.000173	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.22e-05	0.000172	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.19e-05	0.000171	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—RAC1—dilated cardiomyopathy	7.17e-05	0.000171	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.14e-05	0.00017	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.12e-05	0.000169	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.03e-05	0.000167	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—RAC1—dilated cardiomyopathy	7.02e-05	0.000167	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.98e-05	0.000166	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.92e-05	0.000164	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—RAC1—dilated cardiomyopathy	6.91e-05	0.000164	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.9e-05	0.000164	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.89e-05	0.000164	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.89e-05	0.000164	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.88e-05	0.000164	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.85e-05	0.000163	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AGT—dilated cardiomyopathy	6.85e-05	0.000163	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	6.8e-05	0.000162	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.79e-05	0.000162	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—GPX1—dilated cardiomyopathy	6.74e-05	0.00016	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AGT—dilated cardiomyopathy	6.71e-05	0.00016	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.68e-05	0.000159	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.67e-05	0.000159	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AGT—dilated cardiomyopathy	6.6e-05	0.000157	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—CD36—dilated cardiomyopathy	6.57e-05	0.000156	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.56e-05	0.000156	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.38e-05	0.000152	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.27e-05	0.000149	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.26e-05	0.000149	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	6.22e-05	0.000148	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.22e-05	0.000148	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.14e-05	0.000146	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—RAC1—dilated cardiomyopathy	6.14e-05	0.000146	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.13e-05	0.000146	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.05e-05	0.000144	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	6e-05	0.000143	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.97e-05	0.000142	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.95e-05	0.000142	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AGT—dilated cardiomyopathy	5.94e-05	0.000141	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.94e-05	0.000141	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.92e-05	0.000141	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AGT—dilated cardiomyopathy	5.91e-05	0.000141	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.89e-05	0.00014	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AGT—dilated cardiomyopathy	5.86e-05	0.000139	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.83e-05	0.000139	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.81e-05	0.000138	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.73e-05	0.000136	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.72e-05	0.000136	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.71e-05	0.000136	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.64e-05	0.000134	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—RAC1—dilated cardiomyopathy	5.54e-05	0.000132	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.52e-05	0.000131	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—GPX1—dilated cardiomyopathy	5.48e-05	0.00013	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.41e-05	0.000129	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.4e-05	0.000129	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—RAC1—dilated cardiomyopathy	5.35e-05	0.000127	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—CD36—dilated cardiomyopathy	5.33e-05	0.000127	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—RAC1—dilated cardiomyopathy	5.32e-05	0.000127	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.32e-05	0.000126	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AGT—dilated cardiomyopathy	5.29e-05	0.000126	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.27e-05	0.000125	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.2e-05	0.000124	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.19e-05	0.000123	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—RAC1—dilated cardiomyopathy	5.18e-05	0.000123	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.18e-05	0.000123	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.11e-05	0.000122	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AGT—dilated cardiomyopathy	5.11e-05	0.000122	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.1e-05	0.000121	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—RAC1—dilated cardiomyopathy	5.09e-05	0.000121	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AGT—dilated cardiomyopathy	5.08e-05	0.000121	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.08e-05	0.000121	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	5.02e-05	0.000119	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.01e-05	0.000119	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AGT—dilated cardiomyopathy	4.94e-05	0.000118	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	4.89e-05	0.000116	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AGT—dilated cardiomyopathy	4.87e-05	0.000116	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AGT—dilated cardiomyopathy	4.8e-05	0.000114	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.79e-05	0.000114	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—RAF1—dilated cardiomyopathy	4.75e-05	0.000113	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.72e-05	0.000112	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.72e-05	0.000112	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—RAC1—dilated cardiomyopathy	4.7e-05	0.000112	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—RAF1—dilated cardiomyopathy	4.66e-05	0.000111	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.65e-05	0.000111	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—RAC1—dilated cardiomyopathy	4.62e-05	0.00011	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—RAC1—dilated cardiomyopathy	4.61e-05	0.00011	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—RAF1—dilated cardiomyopathy	4.58e-05	0.000109	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	4.52e-05	0.000108	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AGT—dilated cardiomyopathy	4.49e-05	0.000107	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AGT—dilated cardiomyopathy	4.41e-05	0.000105	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AGT—dilated cardiomyopathy	4.41e-05	0.000105	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	4.4e-05	0.000105	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	4.32e-05	0.000103	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.26e-05	0.000101	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	4.2e-05	0.0001	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	4.12e-05	9.81e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.12e-05	9.79e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.1e-05	9.74e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—RAF1—dilated cardiomyopathy	4.07e-05	9.68e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AGT—dilated cardiomyopathy	4.02e-05	9.55e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.98e-05	9.47e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.92e-05	9.32e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—RAF1—dilated cardiomyopathy	3.67e-05	8.74e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.61e-05	8.6e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	3.57e-05	8.49e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.56e-05	8.46e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.55e-05	8.44e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—RAF1—dilated cardiomyopathy	3.55e-05	8.43e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—RAF1—dilated cardiomyopathy	3.53e-05	8.39e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.48e-05	8.28e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	3.48e-05	8.27e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—RAF1—dilated cardiomyopathy	3.43e-05	8.16e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—RAF1—dilated cardiomyopathy	3.38e-05	8.03e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—EGFR—dilated cardiomyopathy	3.26e-05	7.75e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.24e-05	7.69e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	3.19e-05	7.59e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—EGFR—dilated cardiomyopathy	3.14e-05	7.47e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	3.13e-05	7.44e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—RAF1—dilated cardiomyopathy	3.11e-05	7.4e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—RAF1—dilated cardiomyopathy	3.06e-05	7.29e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.06e-05	7.27e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	3e-05	7.13e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.83e-05	6.73e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EGFR—dilated cardiomyopathy	2.79e-05	6.64e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	2.79e-05	6.63e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EGFR—dilated cardiomyopathy	2.52e-05	5.99e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.43e-05	5.78e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EGFR—dilated cardiomyopathy	2.42e-05	5.75e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EGFR—dilated cardiomyopathy	2.35e-05	5.6e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.33e-05	5.55e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EGFR—dilated cardiomyopathy	2.32e-05	5.51e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.27e-05	5.4e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.14e-05	5.08e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.1e-05	5e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.1e-05	4.99e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.06e-05	4.89e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.05e-05	4.87e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.91e-05	4.55e-05	CbGpPWpGaD
